Watch for the moponetug Phase 2 data readout in 1H 2027 as the next major binary catalyst. The company's cash runway appears sufficient to fund operations through key milestones without near-term dilution risk.
Drugs in focus
PRTA drug pipeline →moponetug
◆ Mixed Named in this 8-K- Impact
- Phase
- Phase 2
- Time to market
- If Phase 2 data in 1H 2027 is positive, the program would advance to Phase 3 trials, meaning regulatory approval and commercialization are likely several years away (late 2020s at the earliest).
- Next catalyst
- None dated
What to watchThe next major catalyst is the Phase 2 TargetTau-1 topline readout expected in 1H 2027. Positive data showing both tau biomarker clearance and cognitive benefit could validate the anti-MTBR tau approach and trigger milestone payments from BMS, while negative or mixed results would severely impair Prothena's pipeline value given the recent PRX019 termination. Watch for BMS's Q4 2026 earnings commentary for any trial timing updates.
How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+5- T+0 · Nov 6 $7.97entry
- T+1 · 8d ago +10.10%α +7.73% · $8.78
- T+5 · 4d ago +2.38%α −0.21% · $8.16
- T+6 · todayOpen
- T+20 · in 20d Pending
- T+60 · in 3mo Pending
Price Chart
How similar events traded
Executive Summary
Prothena reported Q3 2026 financial results with a net loss of $16.5M, improved from a $36.5M loss in Q3 2025, driven by lower R&D and G&A expenses. Revenue was minimal at $0.6M for the quarter, while the first nine months included a $50M milestone from Novo. The company has $272.2M in cash, no debt, and maintained 2026 guidance for net cash burn of $18-$23M. Key pipeline catalysts include the moponetug Phase 2 data readout expected in 1H 2027 and Phase 3 trials for prasinezumab and coramitug with primary completions in 2029.
Key Facts
- Q3 2026 net loss of $16.5M vs $36.5M in Q3 2025
- Q3 2026 total revenue of $0.6M vs $2.4M in Q3 2025
- First nine months 2026 total revenue of $52.7M including $50M Novo milestone
- Cash and restricted cash of $272.2M as of September 30, 2026, no debt
- Full year 2026 net cash burn guidance maintained at $18-$23M
- 2,745,380 shares repurchased YTD for $26.6M under $100M buyback program expiring Dec 31, 2026
- Moponetug Phase 2 data readout expected in 1H 2027
- Prasinezumab and coramitug Phase 3 trials primary completion expected in 2029
Financial Impact
Net loss improved by $20.0M YoY in Q3; cash position of $272.2M provides runway of approximately 3+ years at current burn rate
Risk Factors
- All three partnered programs (prasinezumab, coramitug, moponetug) are in early-to-mid stage trials with no approved products
- Phase 3 data for lead programs not expected until 2029, creating a long wait for potential commercialization
- Revenue is entirely dependent on partner milestones and collaboration payments, with no product sales
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001559053-26-000030 |
| Document: prta-20261105.htm | 0001559053-26-000030 |
| Document: 0001559053-26-000030-index-headers.html | 0001559053-26-000030 |
| Document: 0001559053-26-000030-index.html | 0001559053-26-000030 |
| Document: 0001559053-26-000030.txt | 0001559053-26-000030 |
Track record
20 reports on PRTA
8 of 12 bullish or bearish reports moved the stock their way by T+1. Best: +14.11% at T+60 after the Jun 12, 2026 report. 9 of 12 went positive at some point.
Filters
- Nov 13, 20263d ago 3 Neutral 1/10 Entry $8.16 to $7.97 Now $7.97 −2.33% ▼ −2.33% −0.42% vs SPY
- Nov 13, 20263d ago SC 13G/A Neutral 3/10 Entry $8.16 to $7.97 Now $7.97 −2.33% ▼ −2.33% −0.42% vs SPY
- Nov 10, 20266d ago Insider Buy Bullish 5/10 Entry $8.56 to $8.73 Now $7.97 −6.89% ▲ +1.99% +0.67% vs SPY
- Nov 5, 202611d ago 8-K Neutral 4/10 Viewing Entry $7.97 to $8.78 Now $7.97 −0.00% ▲ +10.10% +7.73% vs SPY
- Oct 29, 202618d ago 8-K Bearish 6/10 Entry $8.47 to $8.29 Now $7.97 +5.90% ▲ +2.13% +1.65% vs SPY
- Oct 26, 202621d ago Insider Buy Bullish 5/10 Entry $8.81 to $9.10 Now $7.97 −9.53% ▲ +3.29% +2.95% vs SPY
- Oct 15, 20264w ago Insider Buy Bullish 5/10 Entry $8.35 to $8.48 Now $7.97 −4.55% ▲ +1.56% +1.13% vs SPY
- Sep 30, 20266w ago Insider Buy Bullish 5/10 Entry $8.54 to $8.36 Now $7.97 −6.67% ▼ −2.11% −2.85% vs SPY
- Sep 29, 20266w ago Insider Buy Bullish 5/10 Entry $8.38 to $8.54 Now $7.97 −4.89% ▲ +1.91% +1.73% vs SPY
- Sep 21, 20268w ago Insider Buy Bullish 6/10 Entry $8.99 to $8.68 Now $7.97 −11.35% ▼ −3.45% −2.73% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers